SCHEMBL885984

SCHEMBL885984

O=C(O)c1[nH]c(=O)n(-c2ccccc2)c1-c1cccc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.48
RXFP1 Q9HBX9 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
ALDH1A1 P00352 3/20 0.43
FBP1 P09467 1/20 0.41
CSNK2A1 P68400 2/20 0.40
NOTUM Q6P988 1/20 0.40
USP2 O75604 3/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TOP2A P11388 1/20 0.40
PGR P06401 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885949 0.87 GSK3B (0.44) PIN1ALDH1A1CSNK2A1USP2CYP1A2
SCHEMBL885435 0.84 MDM2 (0.54) PIN1ALDH1A1NOTUMPGRHPGD
SCHEMBL885498 0.83 MAT2A (0.49) RXFP1APOBEC3GALDH1A1CYP1A2CYP2C19
SCHEMBL885490 0.82 REN (0.49) ALDH1A1USP2CYP1A2CYP3A4HSD17B10
SCHEMBL885777 0.78 KMT2A (0.48) RXFP1ALDH1A1CSNK2A1CYP1A2HPGD
SCHEMBL885499 0.73 REN (0.45) ALDH1A1CSNK2A1NOTUMHPGDLMNA
SCHEMBL885660 0.73 KMO (0.52) PIN1ALDH1A1HSD17B10CYP2C9CYP2C19
SCHEMBL885816 0.72 KMT2A (0.46) ALDH1A1CYP1A2HSD17B10HPGDHIF1A
SCHEMBL14705959 0.70 PIN1 (0.54) PIN1ALDH1A1FBP1NOTUMHSD17B10
SCHEMBL2063853 0.69 ALDH1A1 (0.42) ALDH1A1USP2CYP1A2CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT PIN1 2822/4885RXFP1 930/4885APOBEC3G 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.